The ASCO Annual Meeting is the world’s most prominent scientific gathering in the clinical oncology community, showcasing ...

The ASCO Annual Meeting is the world’s most prominent scientific gathering in the clinical oncology community, showcasing cutting-edge research in clinical oncology and advanced cancer therapies. This ...

Patients with chronic myeloid leukemia should be upfront with their care team about how treatment side effects are affecting their daily functioning. When discussing side effects from chronic myeloid ...

Dr Lindsay Rein comments on significant advancements in CML treatment presented at ASH 2024, particularly the approval of asciminib in both the frontline and second-line settings. This new treatment ...

Focusing on the initiation of treatment for newly diagnosed patients with CML, Jorge E. Cortes, MD, details important factors to consider when starting treatment and Claire Saxton discusses strategies ...

The choice of frontline therapy for a patient with chronic phase chronic myeloid leukemia (CP-CML) can have a profound effect on the long-term clinical outcome. Currently, five tyrosine kinase ...

Leukemias are cancers of the blood cells. Chronic myelogenous leukemia (CML) is an uncommon type of cancer of the bone marrow, which produces blood cells. "Myelogenous" refers to the type of blood ...

Please provide your email address to receive an email when new articles are posted on . In this video, Eric Winer, MD, discusses the results of research into chronic myeloid leukemia presented at ASCO ...

A recent study in the British Journal of Haematology by Irani and colleagues suggests that an effector-suppressor score, which is calculated using absolute natural killer (NK) cell, FoxP3 + regulatory ...

Which medicine is best when you are affected by cancer? This can vary from person to person. A new method can help people with a specific type of blood cancer get the best medicine for them. "The new ...